<DOC>
	<DOC>NCT00940641</DOC>
	<brief_summary>The purpose of this study is to evaluate the absorption, distribution, metabolism and excretion of AZD7325 after intravenous and 14C labeled oral dose</brief_summary>
	<brief_title>Assess the Absorption, Distribution, Metabolism and Excretion of AZD7325 After Intravenous and Oral Administration</brief_title>
	<detailed_description />
	<criteria>Healthy subjects Day 1 Body Mass Index (BMI) &gt; 18 and &lt; 30kg/m2 Clinically relevant disease and abnormalities (past or present) which in the opinion of the investigator, may either put the subject at risk to participate in this study or may influence the results of the study or the subject's ability to participate in the study Use of prescription medication within 14 days of the first dose of the investigational product Blood loss in excess of 200 mL within 30 days of Day1 in excess of 500 mL within 90 days of Day1 or in excess of 1350 mL within 1 year of Day1 or donation of blood products within 14 days of Day 1</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Healthy Volunteer</keyword>
</DOC>